Protection from experimental colitis by theaflavin‐3,3′‐digallate correlates with inhibition of IKK and NF‐<i>κ</i>B activation

Abstract

TFDG exerts protective effects in experimental colitis and inhibits production of inflammatory mediators through a mechanism that, at least in part, involves inhibition of NF-kappaB activation.